I question whether ASTRO didn't go too far in their model policy that all proton treatment ought to be part of a randomized clinical trial or registry. On the one hand, I'd love to see that RCT, but on the other hand, I'd like to see some leeway given to new technologies that have met FDA requirements for safety and efficacy. I have written about
this elsewhere, if you're interested:
Proton Therapy – Did ASTRO & Lancet go too far?I agree that proton is not demonstrably better than IMRT, and costs much more. I think the new generation of pencil beam proton machines (e.g., MD Anderson) may be somewhat better than the older ones (e.g., Loma Linda). On the new machines in the short term, rectal SEs seem to be fewer with proton, but that evens out over time. Urinary SEs are about
the same. Sexual SEs do not look very good at all so far. 5-yr recurrence rates look excellent.
I chose SBRT based on the exceptionally low rate of sexual SEs as well as urinary and rectal SEs, and recurrence rate. I would actually love to see a randomized clinical trial between pencil beam proton and SBRT, but I wouldn't hold my breath waiting for it.
- Allen